NOVEL VALIDATED REVERSED-PHASE HIGH-PERFORMANCE LIQUID CHROMATOGRAPHY METHOD FOR DETERMINATION OF GLUCOSAMINE, DIACEREIN, AND METHYL SULFONYL METHANE IN MICRO SAMPLE RAT PLASMA AND ITS APPLICATION TO PHARMACOKINETIC AND DISSOLUTION STUDIES
Objective: The main objective of this research is to develop and validate a simple, specific, precise, sensitive, cost-effective, and rapid reversed-phase high-performance liquid chromatography method for simultaneous quantification of glucosamine (GLU), diacerein (DIA) and methyl sulfonyl methane in bulk and pharmaceutical dosage forms, and micro-sample of rat plasma using ultraviolet (UV) detection, to perform the studies of drug dissolution from tablets.
Methods: Sprague-Dawley rats were used for pharmacokinetic study after intravenous administration of the drug samples at dose 5 mg/kg. The drug samples were extracted by liquid-liquid extraction technique using acetonitrile, which also acted as a deproteinization agent. The separation of the analyte was carried out on a phenomena C18 column with a mobile phase composed of 0.1 % orthophosphoric acid:acetonitrile (80:20 v/v) delivered at a flow rate of 1.0 ml/min, and separation has been monitored by a UV detector, at detection of the wavelength of 285 nm.
Results: This method was proven to be linear over a concentration range of 30–450 μg/ml for GLU, 2–30 μg/ml for DIA, and 10–150 μg/ml for methyl sulfonyl methane with a correlation coefficient of 0.999. The retention time of GLU, DIA, and methyl sulfonyl methane were 2.89, 6.32, and 9.87 min, respectively. Recovery of the drugs was found to be in the range of 98.0–102.0%. Validation results were found to be satisfactory and the method applicable for bulk and formulation analysis. Hence, it was evident that the proposed method was said to be a suitable one for the regular analysis and quality control of pharmaceutical preparations which contain these active drugs either individually or in combination.
Conclusion: The validation results were in good agreement with acceptable limits. Relative standard deviation values which are less than 2.0% are indicating the accuracy and precision of this method. The usefulness of the method is that the common chromatographic conditions have been adopted for assay, dissolution, and pharmacokinetic studies. This developed method showed reliable, precise, and accurate results under optimized conditions.
2. Largo R, Alvarez-Soria MA, Díez-Ortego I, Calvo E, Sánchez-Pernaute O, Herrero-Beaumont G. Glucosamine inhibits IL-1beta-induced NFkappaB activation in human osteoarthritic chondrocytes. Osteoarthr Cart 2003;11:290-8.
3. Available from: http://www.webmed.com/Osteoarthritis/default.htm.
4. Merck Research Laboratories. The Merck Index-an Encyclopedia of Chemicals, Drugs and Biologicals. 14th ed. Whitehouse Station, New Jersey, USA: Merck Research Laboratories; 2006. p. 2980.
5. Indian Pharmacopeial, Government of India. Ministry of Health and Family Welfare. Vol. 2. Ghaziabad: Indian Pharmacopeial Convention; 2010. p. 1191-3.
6. Mahajan A, Singh K, Tandon VR, Kumar S, Kumar H. Diacerein: A new symptomatic slow-acting drug for osteoarthritis. J K Sci 2006;8:173-5.
7. Dougados M, Nguyen M, Berdah L, Mazieres B, Vignon E, Lequesne M. Evaluation of the structure-modifying effects of diacerein in hip osteoarthritis: ECHODIAH, a three-year, placebo-controlled trial. Evaluation of the chondromodulating effect of diacerein in OA of the hip. Arthritis Rheum 2001;44:2539-47.
8. Bruyere O, Burlet N, Delmas PD, Rizzoli R, Cooper C, Reginster JY. Evaluation of symptomatic slow-acting drugs in osteoarthritis using the GRADE system. BMC Musculoskelet Disord 2008;9:165.
9. Available from: http://www.summaries.cochrane.org/CD00511/ Diacereinforosteoarthritis?stash.4FkcgMwp.dpuf.
10. Debord P, Louchahi K, Tod M, Cournot A, Perret G, Petitjean O. Influence of renal function on the pharmacokinetics of diacerein after a single oral dose. Eur J Drug Metab Pharmacokinet 1994;19:13.
11. Magnard O, Louchahi K, Tod M, Petitjean O, Molinier P, Berdah L, et al. Pharmacokinetics of diacerein in patients with liver cirrhosis. Biopharm Drug Dispos 1993;14:401.
12. Fidelix TS, Soares BG, Trevisani VF. Diacerein for osteoarthritis. Cochrane Database Syst Rev 2006;1:CD005117.
13. Richmond VL. Incorporation of methylsulfonylmethane sulfur into guinea pig serum proteins. Life Sci 1986;39:263-8.
14. Ameye LG, Chee WS. Osteoarthritis and nutrition. From nutraceuticals to functional foods: A systematic review of the scientific evidence. Arthritis Res Ther 2006;8:R127.
15. Garcia CV, Paim CS, Steppe M, Schapoval EE. Development of new dissolution test and HPLC-RP method for anti-parasitic ornidazole coated tablets. J Pharm Biomed Anal 2006;41:833.
16. Dumont LM, Berry MR, Nickerson B. J Pharm Biomed Anal 2007;44:79.
17. Vaghela B, Kayastha R, Bhatt N, Pathak NR, Athod D. J Appl Pharm Sci 2011;1:50.
18. Lalitha KG. A simple HPLC method for quantitation of diacerein in tablet dosage form. Eurasian J Anal Chem 2010;5:81-8.
19. Kannappan N, Madhukar A, Srinivasan R, Srinivas RL, Kumar CH, Mannavalan R. Analytical method development and validation of diacerein tablets by RP-HPLC. Int J ChemTech Res 2010;2:143-8.
20. Pashkova E, Pirogov A, Bendryshev A, Ivanaynen E, Shpigun O. J Pharma Biomed Anal 2009;50:671.
21. Reddy MU, Reddy KH, Varaprasad B, Somasekhar P. HPLC method development for glucosamine sulphate and diacerein formulation. J Pharmacol Res 2010;3:361-3.
22. Rani JS, Devanna N. Analytical method development and validation of simultaneous estimation of diacerein, glucosamine and methyl sulfonyl methane by RP-HPLC in pharmaceutical tablet dosage forms. IOSR J Appl Chem 2018;11:47.
This work is licensed under a Creative Commons Attribution 4.0 International License.
The publication is licensed under CC By and is open access. Copyright is with author and allowed to retain publishing rights without restrictions.